WO2003029475A1 - MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF - Google Patents

MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF Download PDF

Info

Publication number
WO2003029475A1
WO2003029475A1 PCT/JP2002/009697 JP0209697W WO03029475A1 WO 2003029475 A1 WO2003029475 A1 WO 2003029475A1 JP 0209697 W JP0209697 W JP 0209697W WO 03029475 A1 WO03029475 A1 WO 03029475A1
Authority
WO
WIPO (PCT)
Prior art keywords
bound
epitope
vector
cells
mammalian cell
Prior art date
Application number
PCT/JP2002/009697
Other languages
English (en)
French (fr)
Inventor
Aikichi Iwamoto
Ai Tachikawa
Original Assignee
Dnavec Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc. filed Critical Dnavec Research Inc.
Priority to KR10-2004-7004307A priority Critical patent/KR20040040475A/ko
Priority to CA002462259A priority patent/CA2462259A1/en
Priority to EP02770209A priority patent/EP1447451A4/en
Priority to JP2003532688A priority patent/JPWO2003029475A1/ja
Priority to US10/489,386 priority patent/US20040265272A1/en
Publication of WO2003029475A1 publication Critical patent/WO2003029475A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2002/009697 2001-09-28 2002-09-20 MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF WO2003029475A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR10-2004-7004307A KR20040040475A (ko) 2001-09-28 2002-09-20 에피토프 결합 β２ｍ을 코드하는 포유동물 세포감염성 바이러스 벡터 및 그의 이용
CA002462259A CA2462259A1 (en) 2001-09-28 2002-09-20 Mammalian cell-infecting virus vector encoding epitope-bound .beta.2m and utilization thereof
EP02770209A EP1447451A4 (en) 2001-09-28 2002-09-20 MAMMALIAN INFECTIVE, EPITOPEED BETA2m CODING VIRUS VECTOR AND ITS USE
JP2003532688A JPWO2003029475A1 (ja) 2001-09-28 2002-09-20 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
US10/489,386 US20040265272A1 (en) 2001-09-28 2002-09-20 Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001301290 2001-09-28
JP2001-301290 2001-09-28

Publications (1)

Publication Number Publication Date
WO2003029475A1 true WO2003029475A1 (en) 2003-04-10

Family

ID=19121729

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009697 WO2003029475A1 (en) 2001-09-28 2002-09-20 MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF

Country Status (7)

Country Link
US (1) US20040265272A1 (ja)
EP (1) EP1447451A4 (ja)
JP (1) JPWO2003029475A1 (ja)
KR (1) KR20040040475A (ja)
CN (1) CN1596311A (ja)
CA (1) CA2462259A1 (ja)
WO (1) WO2003029475A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031380A1 (ja) * 2002-10-01 2004-04-15 Dnavec Research Inc. TAP活性の阻害により MHC class I による外来エピトープの提示を増強する方法
WO2005087269A1 (ja) * 2004-03-16 2005-09-22 Dnavec Research Inc. 腫瘍増殖を抑制する方法
WO2005094878A1 (ja) * 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物
JP2008503214A (ja) * 2004-06-17 2008-02-07 ベックマン コールター インコーポレーティッド ミコバクテリウム・ツベルクローシスのエピトープ、およびその使用法
US7521043B2 (en) 2004-01-13 2009-04-21 Dnavec Research Inc. Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
CN101006172B (zh) * 2004-06-24 2012-09-05 株式会社载体研究所 包含导入了rna病毒的树突状细胞的抗癌剂
JP2017523789A (ja) * 2014-08-06 2017-08-24 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ インターロイキン−２／インターロイキン−２受容体アルファ融合タンパク質および使用方法
US10787494B2 (en) 2018-03-28 2020-09-29 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1248740C (zh) * 2000-03-30 2006-04-05 株式会社载体研究所 使用仙台病毒载体的aids病毒疫苗
US6596206B2 (en) * 2001-03-30 2003-07-22 Picoliter Inc. Generation of pharmaceutical agent particles using focused acoustic energy
CN1902312B (zh) * 2003-11-04 2011-02-23 株式会社载体研究所 制备导入了基因的树突细胞的方法
US20110162093A1 (en) * 2005-06-14 2011-06-30 Yasuji Ueda Methods for producing antibodies
JPWO2007083644A1 (ja) * 2006-01-17 2009-06-11 ディナベック株式会社 新規タンパク質発現系
EP2374470A1 (fr) * 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
CN109354626B (zh) * 2018-11-16 2021-06-18 福州迈新生物技术开发有限公司 抗MyoD1蛋白单克隆抗体、细胞系及其制备方法和应用
WO2021027758A1 (en) * 2019-08-13 2021-02-18 Cure Genetics Co., Ltd. Genetically engineered cells and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO2001018223A1 (fr) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001057204A1 (fr) * 2000-02-02 2001-08-09 Yasufumi Kaneda Vecteur d'enveloppe virale pour transfert de gene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869270A (en) * 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
AU4545799A (en) * 1998-06-10 1999-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Beta2 microglobulin fusion proteins and high affinity variants
GB0026812D0 (en) * 2000-11-02 2000-12-20 Isis Innovation Cancer therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024290A1 (en) * 1993-04-08 1994-10-27 British Bio-Technology Limited Fusion proteins between antigenic amino acid sequences and beta-2-microglobulin
WO2001018223A1 (fr) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001057204A1 (fr) * 2000-02-02 2001-08-09 Yasufumi Kaneda Vecteur d'enveloppe virale pour transfert de gene

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
KATO A. ET AL.: "The paramyxovirus, sendai virus, V protein encodes a luxury function required for viral pathogenesis", EMBO J., vol. 16, no. 3, 1997, pages 578 - 587, XP000941467 *
RAMANI K. ET AL.: "Site-specific gene delivery in vivo through engineered Seandai viral envelopes", PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 11886 - 11890, XP002942034 *
See also references of EP1447451A4 *
TAFURO S. ET AL.: "Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2, fusion molecules", EUR. J. IMMUNOL., vol. 31, no. 2, February 2001 (2001-02-01), pages 440 - 449, XP002959839 *
TOSHITANI K. ET AL.: "Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes", PROC. NATL. ACAD. SCI. USA, vol. 93, no. 1, 1996, pages 236 - 240, XP002051157 *
UGER R.A. ET AL.: "Covalent linkage to beta 2-microglobulin enhances the MHC stability and antigenicity of suboptimal CTL epitopes", J. IMMUNOL., vol. 162, no. 10, 1999, pages 6024 - 6028, XP002959840 *
UGER R.A., BARBER B.H.: "Creating CTL targets with epitope-linked beta 2-microglobulin constructs", J. IMMUNOL., vol. 160, no. 4, 1998, pages 1598 - 1605, XP002115504 *
WHITE J. ET AL.: "Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma", J. IMMUNOL., vol. 162, no. 5, 1999, pages 2671 - 2676, XP002959841 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031380A1 (ja) * 2002-10-01 2004-04-15 Dnavec Research Inc. TAP活性の阻害により MHC class I による外来エピトープの提示を増強する方法
US7521043B2 (en) 2004-01-13 2009-04-21 Dnavec Research Inc. Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
WO2005087269A1 (ja) * 2004-03-16 2005-09-22 Dnavec Research Inc. 腫瘍増殖を抑制する方法
WO2005094878A1 (ja) * 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物
JP2008503214A (ja) * 2004-06-17 2008-02-07 ベックマン コールター インコーポレーティッド ミコバクテリウム・ツベルクローシスのエピトープ、およびその使用法
US8889118B2 (en) 2004-06-24 2014-11-18 Dna Vec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
CN101006172B (zh) * 2004-06-24 2012-09-05 株式会社载体研究所 包含导入了rna病毒的树突状细胞的抗癌剂
JP2017523789A (ja) * 2014-08-06 2017-08-24 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ インターロイキン−２／インターロイキン−２受容体アルファ融合タンパク質および使用方法
JP2021000084A (ja) * 2014-08-06 2021-01-07 ユニバーシティー オブ マイアミＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉａｍｉ インターロイキン−２／インターロイキン−２受容体アルファ融合タンパク質および使用方法
JP7272663B2 (ja) 2014-08-06 2023-05-12 ユニバーシティー オブ マイアミ インターロイキン－２／インターロイキン－２受容体アルファ融合タンパク質および使用方法
US12084483B2 (en) 2014-08-06 2024-09-10 University Of Miami Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US10787494B2 (en) 2018-03-28 2020-09-29 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US11359000B2 (en) 2018-03-28 2022-06-14 Bristol-Myers Squibb Company Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use

Also Published As

Publication number Publication date
EP1447451A4 (en) 2006-06-07
US20040265272A1 (en) 2004-12-30
KR20040040475A (ko) 2004-05-12
EP1447451A1 (en) 2004-08-18
CA2462259A1 (en) 2003-04-10
JPWO2003029475A1 (ja) 2005-01-20
CN1596311A (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
WO2003029475A1 (en) MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF
MXPA04004634A (es) Expresion policistronica de anticuerpos.
Retière et al. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response
Assenmacher et al. Commitment of individual Th1-like lymphocytes to expression of IFN-γ versus IL-4 and IL-10: selective induction of IL-10 by sequential stimulation of naive Th cells with IL-12 and IL-4
Wagner et al. Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display
Rist et al. Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition
ATE312920T1 (de) Dna immunisierung gegen chlamydia infektion
AU3912497A (en) Purification of antigen-specific t cells
SE9103183L (sv) Virus-antikroppskomplex
DK1597280T3 (da) Fremstilling af monoklone antistoffer ved EBV-transformation af B-celler
Duraiswamy et al. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions
CN101381402B (zh) Ny-eso-1肿瘤抗原模拟表位及其应用
EP1980573A3 (en) Isolated dendritic cell membrane protein genes
Fatehi et al. Time-delayed model of autoimmune dynamics
Morita et al. Cutting edge: T cells monitor N-myristoylation of the Nef protein in simian immunodeficiency virus-infected monkeys
Merritt et al. On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation
CA2327434A1 (en) Dna immunization against chlamydia infection
He et al. Procedure for preparing peptide-major histocompatibility complex tetramers for direct quantification of antigen-specific cytotoxic T lymphocytes
Archambaud et al. STAT6 deletion converts the Th2 inflammatory pathology afflicting LatY136F mice into a lymphoproliferative disorder involving Th1 and CD8 effector T cells
FR2843115B1 (fr) Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
Wang et al. Prediction and identification of human leukocyte antigen‑A2‑restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein
CA2084521A1 (en) Hepatitis c virus antigen polypeptide, production method therefor, and antibody detection method
DK0536178T3 (da) Assay for cytotoksiske T-celler
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
TW200701986A (en) Peptide antigen of human papilloma virus type 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003532688

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047004307

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2462259

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002770209

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002823703X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 10489386

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002770209

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002770209

Country of ref document: EP